OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Showing 9 citing articles:
Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression
José M. Rodriguez‐Valadez, Malak Tahsin, Kirsten E. Fleischmann, et al.
Diabetes Care (2023) Vol. 46, Iss. 6, pp. 1300-1310
Open Access | Times Cited: 27
José M. Rodriguez‐Valadez, Malak Tahsin, Kirsten E. Fleischmann, et al.
Diabetes Care (2023) Vol. 46, Iss. 6, pp. 1300-1310
Open Access | Times Cited: 27
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study
Mohammed Alharbi, Abdullah Othman, Ahmed Nahari, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1120-1150
Open Access | Times Cited: 4
Mohammed Alharbi, Abdullah Othman, Ahmed Nahari, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1120-1150
Open Access | Times Cited: 4
Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
Spyros Kolovos, L Bellanca, Harinala Groyer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3385-3397
Open Access | Times Cited: 6
Spyros Kolovos, L Bellanca, Harinala Groyer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3385-3397
Open Access | Times Cited: 6
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia
Yazed AlRuthia, Khaled H. Aburisheh, Sondus Ata, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102057-102057
Open Access | Times Cited: 1
Yazed AlRuthia, Khaled H. Aburisheh, Sondus Ata, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102057-102057
Open Access | Times Cited: 1
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
Reimar W. Thomsen, Lotte W. B. Christensen, Johnny Kahlert, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 11-12, pp. 1891-1906
Open Access | Times Cited: 4
Reimar W. Thomsen, Lotte W. B. Christensen, Johnny Kahlert, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 11-12, pp. 1891-1906
Open Access | Times Cited: 4
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
Ryan Pulleyblank, Nikolaj Birk Larsen
PharmacoEconomics - Open (2023) Vol. 7, Iss. 4, pp. 579-591
Open Access | Times Cited: 1
Ryan Pulleyblank, Nikolaj Birk Larsen
PharmacoEconomics - Open (2023) Vol. 7, Iss. 4, pp. 579-591
Open Access | Times Cited: 1
